BIOMARK ANNOUNCES PATENT GRANTED IN CHINA
Vancouver, British Columbia – (October 25th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRASFERASE” has been prosecuted to allowance and issued in China. Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]
BIOMARK ANNOUNCES APPOINTMENT OF SCIENTIFIC AND MEDICAL ADVISORS
Vancouver, British Columbia – (October 2nd, 2017)– BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed four distinguished experts to its scientific and medical advisory team. Announcements related to each adviser will be made through appropriate news release. Over the past few months our new advisors […]
BIOMARK ANNOUNCES MULTIPLE PATENTS ISSUED
Press_Release_BIOMARK_ANNOUNCES_MULTIPLE_PATENTS_ISSUED_ (PDF)
BIOMARK Closes First Tranche of Over-Subscribed Private Placement Offering
Press Release – Biomark Closes First Tranche of Private Placement Offering (PDF)
BIOMARK Appoints Ms. Guoyu Huang As Interim CFO
Press Release – BIOMARK APPIONTS MS GUOYU HUANG AS INTERIM CFO (PDF)
BioMark Announces Private Placement Offering
Press Release – Biomark Announces Private Placement-March 9 2016 (PDF) ———————————————
BIOMARK Closes Previous Announced Private Placement Offering
Press_Release_-_Biomark_Closes_Private_Placement_announced_on_June_24_2016 (PDF)
BIOMARK Selected to Pitch at 2017 BCTECH Summit
News Release – BIOMARK Selected To Pitch At BCTech Summit 2017 (PDF)
BIOMARK Invited to Project Pitch Stage For GAPP Application
News Release – BIOMARK’s GAPP Success (PDF)
A supramolecular indicator displacement assay for acetyl amantadine
A supramolecular indicator displacement assay for acetyl amantadine, a proxy biomarker for spermidine/spermine N1-acetyltransferase (SSAT) activity Introduction Cancer is a leading cause of death worldwide.1 The number of new cancer cases is expected to increase 40% in the next 15 years in Canada due to an aging and growing population.2 Lung cancer is the most […]